Outlook Therapeutics (OTLK) Cash from Operations: 2015-2024
Historic Cash from Operations for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to -$68.8 million.
- Outlook Therapeutics' Cash from Operations fell 103.25% to -$12.1 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$31.8 million, marking a year-over-year increase of 1.55%. This contributed to the annual value of -$68.8 million for FY2024, which is 60.08% down from last year.
- Per Outlook Therapeutics' latest filing, its Cash from Operations stood at -$68.8 million for FY2024, which was down 60.08% from -$43.0 million recorded in FY2023.
- In the past 5 years, Outlook Therapeutics' Cash from Operations ranged from a high of -$31.8 million in FY2020 and a low of -$68.8 million during FY2024.
- Over the past 3 years, Outlook Therapeutics' median Cash from Operations value was -$56.7 million (recorded in 2022), while the average stood at -$56.1 million.
- In the last 5 years, Outlook Therapeutics' Cash from Operations tumbled by 70.66% in 2021 and then climbed by 24.18% in 2023.
- Yearly analysis of 5 years shows Outlook Therapeutics' Cash from Operations stood at -$31.8 million in 2020, then plummeted by 70.66% to -$54.3 million in 2021, then decreased by 4.46% to -$56.7 million in 2022, then climbed by 24.18% to -$43.0 million in 2023, then crashed by 60.08% to -$68.8 million in 2024.